Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosis.
Michel L, Jean-Louis F, Begue E, Bensussan A, Bagot M.
Blood. 2013 Feb 21;121(8):1477-8. doi: 10.1182/blood-2012-10-460535. No abstract available.
Related citations
A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR, Whittaker S.
Skin Therapy Lett. 2012 Dec;17(10):5-9. Review.
Development of a plaque infiltrated with large CD30+ T cells over a silicone-containing device in a patient with history of Sézary syndrome.
Engberg AK, Bunick CG, Subtil A, Ko CJ, Girardi M.
J Clin Oncol. 2013 Feb 20;31(6):e87-9. doi: 10.1200/JCO.2012.42.9241. Epub 2012 Nov 26. No abstract available.
From single-cell signature to prognostic factors: the case of Sézary syndrome.
Scala E, Narducci MG, Russo G.
Expert Rev Clin Immunol. 2012 Nov;8(8):699-701. doi: 10.1586/eci.12.75. No abstract available.
Can the level of CD52 expression on Sézary cells be used to predict the response of Sézary syndrome to alemtuzumab?
Fernandes IC, Gonçalves M, dos Anjos Teixeira M, Gonçalves C, Coutinho J, Selores M, Alves R, Lima M.
J Am Acad Dermatol. 2012 Nov;67(5):1083-5. doi: 10.1016/j.jaad.2012.05.010. No abstract available.
Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
Choi MY, Lechowicz MJ.
Cancer J. 2012 Sep-Oct;18(5):439-44. Review.
Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome.
Martin SJ, Duvic M.
Int J Dermatol. 2012 Oct;51(10):1195-8. doi: 10.1111/j.1365-4632.2011.05204.x.
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbé C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM.
Eur J Cancer. 2013 Jan;49(2):386-94. doi: 10.1016/j.ejca.2012.08.017. Epub 2012 Sep 13.
Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series.
Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M.
Cancer. 2013 Feb 15;119(4):825-31. doi: 10.1002/cncr.27740. Epub 2012 Sep 5.
Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
Gibson HM, Mishra A, Chan DV, Hake TS, Porcu P, Wong HK.
J Invest Dermatol. 2013 Jan;133(1):249-57. doi: 10.1038/jid.2012.265. Epub 2012 Sep 6.
Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
Lee CS, Ungewickell A, Bhaduri A, Qu K, Webster DE, Armstrong R, Weng WK, Aros CJ, Mah A, Chen RO, Lin M, Sundram U, Chang HY, Kretz M, Kim YH, Khavari PA.
Blood. 2012 Oct 18;120(16):3288-97. doi: 10.1182/blood-2012-04-423061. Epub 2012 Aug 30.
A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
van der Fits L, Rebel HG, Out-Luiting JJ, Pouw SM, Smit F, Vermeer KG, van Zijl L, Tensen CP, Weijer K, Vermeer MH.
Exp Dermatol. 2012 Sep;21(9):706-9. doi: 10.1111/j.1600-0625.2012.01556.x.
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.
Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W, Duvic M.
Clin Cancer Res. 2012 Sep 15;18(18):5051-60. doi: 10.1158/1078-0432.CCR-12-0604. Epub 2012 Jul 31.
Sezary syndrome presenting with tumourous involvement of the breast detected by (18) F-fluorodeoxyglucose positron-emission tomography/computed tomography.
Tadmor T, Attias D, Polliack A.
Br J Haematol. 2012 Aug;158(4):432. doi: 10.1111/j.1365-2141.2012.09216.x. Epub 2012 Jul 5. No abstract available.
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome.
Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M.
Leuk Lymphoma. 2013 Jan;54(1):69-75. doi: 10.3109/10428194.2012.706286. Epub 2012 Sep 14.
Thymopentin down-regulates both activity and expression of iNOS in blood cells of Sézary syndrome patients.
Patruno A, Tosco P, Borretto E, Franceschelli S, Amerio P, Pesce M, Guglielmo S, Campiglia P, Bernengo MG, Fruttero R.
Nitric Oxide. 2012 Oct 15;27(3):143-9. doi: 10.1016/j.niox.2012.06.002. Epub 2012 Jun 18.
NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L, Qin Y, Out-Luiting JJ, Vermeer KG, Whittaker S, van Es JH, Tensen CP, Vermeer MH.
J Invest Dermatol. 2012 Dec;132(12):2810-7. doi: 10.1038/jid.2012.203. Epub 2012 Jun 21.
Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Schwingshackl P, Obermoser G, Nguyen VA, Fritsch P, Sepp N, Romani N.
Acta Derm Venereol. 2012 May;92(3):269-75. doi: 10.2340/00015555-1220.
Sézary syndrome: a study of 176 patients at Mayo Clinic.
Kubica AW, Davis MD, Weaver AL, Killian JM, Pittelkow MR.
J Am Acad Dermatol. 2012 Dec;67(6):1189-99. doi: 10.1016/j.jaad.2012.04.043. Epub 2012 May 27.
Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma.
Bégué E, Jean-Louis F, Bagot M, Jauliac S, Cayuela JM, Laroche L, Parquet N, Bachelez H, Bensussan A, Courtois G, Michel L.
Blood. 2012 Jul 5;120(1):143-54. doi: 10.1182/blood-2011-09-379156. Epub 2012 May 24.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on